Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy

被引:0
作者
Anwar R. Padhani
Aftab Alam Khan
机构
[1] Mount Vernon Hospital,Consultant Radiologist and Head of Imaging Research, Paul Strickland Scanner Centre
来源
Targeted Oncology | 2010年 / 5卷
关键词
Dynamic contrast enhanced; Diffusion; MRI; Biomarker; Cellularity; Perfusion; Functional imaging; Response monitoring; Radiotherapy; Antiangiogenesis;
D O I
暂无
中图分类号
学科分类号
摘要
There is an increasing awareness that anatomical approaches based on measurements of tumor size have significant limitations for assessing therapy response. Functional imaging techniques are increasing being used to monitor response to therapies with novel mechanisms of action, often predicting the success of therapy before conventional measurements have changed. Dynamic contrast-enhanced and diffusion magnetic resonance imaging (MRI) are the most advanced in their evidence base, and in this manuscript we focus on them as response parameters. Technology, data gathering methods, and current limitations for these techniques are addressed. With few exceptions, most studies shows that successful treatment is reflected by increases in tumor water diffusion values visible as increased apparent diffusion coefficient values. Most response assessment studies also show that successful treatment results in decreases in tumor vascularization and microvessel permeability.
引用
收藏
页码:39 / 52
页数:13
相关论文
共 292 条
[1]  
Eisenhauer EA(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[2]  
Therasse P(2004)Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society Br J Cancer 90 2256-2260
[3]  
Bogaerts J(2007)We should desist using RECIST, at least in GIST J Clin Oncol 25 1760-1764
[4]  
Husband JE(2008)A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors J Clin Oncol 26 3550-2019
[5]  
Schwartz LH(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2676
[6]  
Spencer J(2007)Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666-799
[7]  
Benjamin RS(2005)Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792-598
[8]  
Choi H(2006)Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies J Natl Cancer Inst 98 580-54
[9]  
Macapinlac HA(2008)Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs Nat Clin Pract Oncol 5 44-262
[10]  
Nathan P(2007)Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed? Radiology 244 257-1628